At ASCO 2020 meeting, the new final survival results of the SPARTAN study were reported. When we look at overall survival in SPARTAN, the use of apalutamideprolongs survival from 60 months to 74 months – that is a 14-month survival advantage, with a hazard ratioof 0.78. Earlier reports have shown significant advantages in reduction of ...

CheckMate 9LA is the second trial in a row of trials investigating the role of immunotherapy combinations in patients with non-small cell lung cancer (NSCLC). At the preplanned interim analysis after 8.1 months, overall survival was significantly prolonged with the combination of ipilimumab (IPI) and nivolumab (NIVO) and chemo vs chemo alone as front-line therapy in unselected patients with advanced ...

Professor Martin Reck explaining the background for CheckMate 9LA-study and the effect of the combination of nivolumab and ipilimumab + 2 cycles of chemotherapy as first-line treatment of stage IV/recurrent non-small cell lung ...

In this MEDtalk Eric J. Small, MD and principal investigator of the SPARTAN study describe what characterizes the group of patients with nonmetastatic castration-resistant prostate ...

In this MEDtalk Eric J. Small, MD and principal investigator of the SPARTAN study, explains the clinical benefits from early treatment of patients with nonmetastatic castration-resistant prostate ...

In this MEDtalk, Eric J. Small talks about to which extent patients with non-metastatic castration-resistant prostate cancer achieve metastasis-free survival and whether it is possible to delay the time until chemotherapy, as well as the impact of treatment on ...

MEDtalk: Background and study design of the SPARTAN study

ASCO20 Virtual | Best Practice Nordic | 3. Jun 2020 kl. 12:35 | ,

Eric J. Small, MD and principal investigator of the SPARTAN study explains the background and study design of the SPARTAN study, where the efficiency and safety of apalutamide for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) was ...

The COVID-19 pandemic has changed the format of this year’s ASCO Annual Meeting. The conference ran from 29 – 31 May under the theme ‘Unite and Conquer: Accelerating Progress Together.’ This year’s scientific program featured more than 250 oral presentations and 2,500 poster presentations in 24 disease-based and specialty tracks. In the opening session on ...

Results from a post hoc analysis of the SPARTAN Phase III study of apalutamide showed that regardless of genetic subclass, the treatment significantly improved the metastasis-free survival of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). For more than 50% of patients treated with apalutamide, a ≥ 90% reduction in PSA was observed. The results was ...

Three new therapeutic agents for the treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC), apalutamid, darolutamid and enzalutamid, have recently been FDA approved. Not alone are the therapies new, they also open up to the treatment of a whole new group of patients, for whom there was no treatment possibility earlier. It raises several questions. On ...

#Senaste tidskrift

BestPractice Nordic

Nr. 1 • mars 2020
1. Årgang
  • Hjärt-kärlsjukdom
  • Blodtrycksmätning
  • Inkretinbehandling